...
首页> 外文期刊>Drug development and industrial pharmacy >Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach
【24h】

Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach

机译:通过设计(QBD)方法,使用质量的核苷酸盐酸尼卡丁盐酸盐的持续胃保留片剂的发展

获取原文
获取原文并翻译 | 示例

摘要

The objective of the present study was to develop a sustained release gastro-retentive (SRGR) tablet formulation of nicardipine hydrochloride (HCl) for once-a-day dosing using the quality by design (QbD) approach. The quality target product profile of nicardipine HCl SRGR tablet formulation was defined, and critical quality attributes (CQAs) were identified. Potential risk factors were identified using a fish bone diagram and failure mode effect analysis (FMEA) tool and screened by the Plackett–Burman design, and finally nicardipine HCl SRGR tablet formulation was optimized using the Box–Behnken design. The tablets were prepared by a direct compression technique using polymers such as hydroxypropylmethylcellulose (HPMC K15M), glyceryl behenate, alone or in combinations and other standard excipients. Sodium bicarbonate was incorporated as a gas-generating agent. The effects of polymers and sodium bicarbonate on the drug release profile and floating properties were investigated as these parameters are likely to affect the desired once-a-day dosing regimen and finally the therapeutic efficacy of SRGR drug delivery systems. It was observed that formulation variables X 1 : Glyceryl behenate (mg/tab) and X 2 : HPMC K15M (mg/tab) strikingly influenced the drug release (%) (Y 1 ), whereas floating lag time (min) (Y 2 ) was significantly impacted by the formulation variable X 3 : Sodium bicarbonate (mg/tab). A design space plot within which the CQAs remained unchanged was established at a lab scale. In conclusion, this study demonstrated the suitability of a glyceryl behenate-HPMC K15M polymer combination along with sodium bicarbonate to achieve SRGR tablet formulation for once-a-day dosing of nicardipine HCl using the systematic QbD approach.
机译:本研究的目的是开发一种持续的胃脂钙化(SRGR)片剂配方,用于使用设计(QBD)方法使用质量的一次性给药。确定了Nicardipine HCl SRGR片剂配方的质量目标产物型材,并确定了临界质量属性(CQAS)。使用鱼骨图和失效模式效果分析(FMEA)工具鉴定出潜在的危险因素,并由Plackett-Burman设计筛选,最后使用Box-Behnken设计进行了Nicardipine HCl SRGR片剂配方。通过使用聚合物如羟丙基甲基纤维素(HPMC K15M),甘油蛋白,单独或组合和其他标准赋形剂,通过直接压缩技术制备片剂。碳酸氢钠掺入作为气体发生剂。研究了聚合物和碳酸氢钠对药物释放曲线和浮动性质的影响,因为这些参数可能影响所需的一次性给药方案,最后是SRGR药物递送系统的治疗效果。观察到制剂变量x 1:甘油蛋白(mg /突片)和x 2:hpmc K15m(mg / tab)尖锐地影响了药物释放(%)(y 1),而浮动滞后时间(min)(y 2 )由制剂X 3:碳酸氢钠(Mg / Tab)显着影响。在实验室规模建立CQAS保持不变的设计空间曲线图。总之,本研究证明了糖类甘露糖蛋白-HPMC K15M聚合物组合的适用性以及碳酸氢钠,以实现SRGR片剂配方,用于使用系统QBD方法进行一次使用Nicardipine HCl的一次性剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号